Rilapladib structure
|
Common Name | Rilapladib | ||
|---|---|---|---|---|
| CAS Number | 412950-08-4 | Molecular Weight | 735.80500 | |
| Density | 1.36g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C40H38F5N3O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RilapladibRilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM. |
| Name | 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-N-[1-(2-methoxyethyl)piperidin-4-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide |
|---|---|
| Synonym | More Synonyms |
| Description | Rilapladib is a selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) inhibitor with an IC50 of 230 pM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 230 pM (Lp-PLA2)[1]. |
| References |
| Density | 1.36g/cm3 |
|---|---|
| Molecular Formula | C40H38F5N3O3S |
| Molecular Weight | 735.80500 |
| Exact Mass | 735.25500 |
| PSA | 80.08000 |
| LogP | 8.33530 |
| Storage condition | 2-8℃ |
|
~82%
Rilapladib CAS#:412950-08-4 |
| Literature: GLAXO GROUP LIMITED; LEE, Mei-yin Patent: WO2013/30374 A1, 2013 ; Location in patent: Page/Page column 22; 23 ; |
| MTdU |
| Rilapladib |
| UNII-O14CWE893Z |